Pharvaris (PHVS) Stock Analysis Report

General Information

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks.

By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Pharvaris (PHVS) Stock Graph

How We Grade Pharvaris (PHVS)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Pharvaris (PHVS) across the board compared to its closest peers.

Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

78.68

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Peer Ratings

See how Pharvaris compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers

Value

Quality

Growth

Momentum

Short

Medium

Long

PBHPrestige Consumer

34.31

6.57

87.45

15.41

OCULOcular Therapeutix

N/A

6.67

BHCBausch Health Companies

26.71

N/A

10.1

72.36

TRLVTrulieve Cannabis

N/A

Short: price trend over the last couple of months

Medium: price trend over the last couple of quarters

Long: price trend over the past year

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Future Growth

Our estimate of future price growth is based on an aggregation of 12 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $40.00 - $79.00 with an average of $57.77

80.42%

Expected movement for Pharvaris (PHVS) over the next 12 months

Based on these rankings

Recent Ratings for Pharvaris (PHVS)

Guggenheim

Date:

Sep 10, 2026

Action:

Maintains

Prev. Target:

$40.00

New Target:

$44.00

Morgan Stanley

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$46.00

New Target:

$62.00

Leerink Partners

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$50.00

New Target:

$65.00

Wells Fargo

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$55.00

New Target:

$65.00

RBC Capital

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$52.00

New Target:

$62.00

Citizens

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$75.00

New Target:

$79.00

Wedbush

Date:

Sep 9, 2026

Action:

Maintains

Prev. Target:

$42.00

New Target:

$50.00

HC Wainwright & Co.

Date:

Sep 8, 2026

Action:

Reiterates

Prev. Target:

$60.00

New Target:

$60.00

Wedbush

Date:

Sep 8, 2026

Action:

Reiterates

Prev. Target:

$42.00

New Target:

$42.00

Past Performance

How has Pharvaris (PHVS) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Pharvaris (PHVS) sharpe ratio over the past 5 years is 0.2300 which is considered to be above average compared to the peer average of 0.2209

Company Financials

INCOME STATEMENT

The income statement also known as the profit and loss statement, primarily focuses on the company's revenues and expenses during a particular period.

The main purpose of an income statement is to convey details of profitability and business activities. Below, is PHVS's income statement for the previous four years along with its trailing-twelve- month profit & loss.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Total Revenue

0.00

Operating Revenue

0.00

Cost Of Revenue

—

Gross Profit

—

Operating Expense

0.09

0.10

0.15

0.17

0.18

Selling General And Administration

0.03

0.05

Research and Development

0.06

0.07

0.10

0.12

0.13

Operating Income

-0.09

-0.10

-0.15

-0.17

-0.18

Net Non-Operating Interest Income Expense

—

0.00

0.01

Other Income Expense

0.01

—

-0.01

—

Other Non-Operating Income Expenses

—

Pre-Tax Income

-0.08

-0.10

-0.13

-0.17

Tax Provision

0.00

Net Income

-0.08

-0.10

-0.13

-0.18

-0.17

Net Income Common Stockholders

-0.08

-0.10

-0.13

-0.18

-0.17

Total Operating Income As Reported

—

Total Expenses

0.09

0.10

0.15

0.17

0.18

Net Income From Continuing And Discontinued Operation

-0.08

-0.10

-0.13

-0.18

-0.17

Normalized Income

-0.08

-0.10

-0.14

-0.17

Interest Income

—

Interest Expense

—

Net Interest Income

—

0.00

0.01

EBIT

-0.08

-0.10

-0.15

-0.17

-0.18

EBITDA

-0.08

-0.10

-0.15

-0.17

-0.18

Reconciled Cost Of Revenue

—

Reconciled Depreciation

0.00

Normalized EBITDA

-0.09

-0.15

-0.16

-0.18

Tax Rate For Calcs

0.00

0.40

Tax Effect Of Unusual Items

0.00

BALANCE SHEET

The balance sheet is a snapshot of a companies financials during a particular period in time.

It breaks down what company owns (assets) and what a company owes (liabilities), in order to give investors an overview of its capital structure.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Total Assets

0.17

0.40

0.29

0.30

0.33

Current Assets

0.17

0.40

0.29

0.30

0.33

Total Non-Current Assets

0.00

Total Liabilities Net Minority Interest

0.02

0.01

0.02

0.03

Current Liabilities

0.02

0.01

0.02

0.03

Other Non-Current Liabilities

—

Total Equity Gross Minority Interest

0.15

0.38

0.27

0.30

Stockholders Equity

—

Total Capitalization

0.15

0.38

0.27

0.30

Common Stock Equity

0.15

0.38

0.27

0.30

Net Tangible Assets

0.15

0.38

0.27

0.30

Working Capital

0.15

0.38

0.27

0.30

Invested Capital

0.15

0.38

0.27

0.30

Tangible Book Value

0.15

0.38

0.27

0.30

Total Debt

0.00

Net Debt

—

Share Issued

0.03

0.05

0.07

Ordinary Shares Number

0.03

0.05

0.07

CASH FLOW STATEMENTS

A companies statement of cash flows gives an investor a break down of the cash inflows and outflows from a companies operations and investment activities.

FISCAL YEAR (BIL.)

2022 ($)

2023 ($)

2024 ($)

2025 ($)

TTM ($)

Cash Flow from Continuing Operating Activities

-0.07

-0.09

-0.12

-0.14

-0.16

Net Income from Continuing Operations

-0.08

-0.10

-0.13

-0.17

Depreciation and Amortization

0.00

Deferred Tax

—

Deferred Income Tax

—

Stock-Based Compensation

0.01

0.02

Other Non-Cash Items

0.00

-0.01

0.00

Change in Working Capital

0.01

-0.01

0.01

0.00

Change in Receivables

0.00

Changes in Account Receivables

—

Change in Inventory

—

Change in Payables and Accrued Expense

0.01

0.00

0.01

0.00

Change in Payable

0.00

-0.01

Change in Account Payable

—

Change in Other Current Assets

0.00

Change in Other Current Liabilities

—

Change in Other Working Capital

—

Cash Flow from Continuing Investing Activities

0.00

Net PPE Purchase and Sale

0.00

Net Business Purchase and Sale

—

Purchase of Business

—

Net Investment Purchase and Sale

—

Purchase of Investment

—

Sale of Investment

—

Net Other Investing Changes

—

Financing Cash Flow

0.01

0.33

0.00

0.16

0.27

Cash Flow from Continuing Financing Activities

0.01

0.33

0.00

0.16

0.27

Net Issuance Payments of Debt

0.00

Net Long-Term Debt Issuance

0.00

Long-Term Debt Issuance

—

Long-Term Debt Payments

0.00

Net Short-Term Debt Issuance

—

Net Common Stock Issuance

0.01

0.34

0.00

0.17

0.28

Common Stock Issuance

0.01

0.34

0.00

0.17

0.28

Common Stock Payments

—

Cash Dividends Paid

—

Net Other Financing Charges

0.00

—

0.00

—

End Cash Position

0.76

0.86

1.30

1.06

1.19

Changes in Cash

-0.06

0.23

-0.12

0.02

0.11

Beginning Cash Position

0.80

0.63

1.41

1.05

1.07

Capital Expenditure

0.00

—

0.00

Issuance of Capital Stock

0.01

0.34

0.00

0.17

0.28

Issuance of Debt

—

Repayment of Debt

0.00

Repurchase of Capital Stock

—

Free Cash Flow

-0.07

-0.09

-0.12

-0.14

-0.16

Pharvaris

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL